Literature DB >> 8063020

Epidemiology of genital herpes.

G R Kinghorn1.   

Abstract

New serological methods, based on the detection of type-specific antibodies to herpes simplex virus (HSV) glycoproteins, have allowed a reappraisal of the prevalence of genital herpes. During the 1980s, genital herpes continued to be an infection of epidemic proportions in many developed countries. In the USA, although there was evidence of a decline in the age-specific prevalence of HSV type 1 (HSV-1) infection, the seroprevalence of HSV type 2 (HSV-2) has continued to increase. Among those attending sexually transmitted disease clinics in the USA, 30-50% of adults now have antibodies to HSV-2. Only a minority of HSV-2 infected persons present with clinical disease related to this infection. In some countries, an increase in the incidence of severe primary genital infections caused by HSV-1, which often occur in monogamous relationships, has been reported. Genital ulcer disease, of which genital herpes is the most common cause in developed countries, is an important risk factor for the acquisition and transmission of human immunodeficiency virus (HIV) infection. Furthermore, evidence is accruing for a potential role of HSV reactivation in the progression of immune deficiency in HIV-infected individuals.

Entities:  

Mesh:

Year:  1994        PMID: 8063020

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  12 in total

1.  Performance of two commercial enzyme-linked immunosorbent assay kits using recombinant glycoprotein G2 antigen for detection of herpes simplex virus type 2 specific antibodies.

Authors:  Sharmila M Reddy; P Balakrishnan; S Uma; S P Thyagarajan; Suniti Solomon
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

2.  Towards an effective genital herpes vaccine: past lessons and future prospects.

Authors:  William P Halford
Journal:  Future Virol       Date:  2007-01-01       Impact factor: 1.831

3.  The international development of the RGHQoL: a quality of life measure for recurrent genital herpes.

Authors:  L C Doward; S P McKenna; T Kohlmann; M Niero; D Patrick; B Spencer; H Thorsen
Journal:  Qual Life Res       Date:  1998-02       Impact factor: 4.147

4.  Evaluation of confirmatory strategies for detection of type-specific antibodies against herpes simplex virus type 2.

Authors:  Bodo Rolf Eing; Lars Lippelt; Eva Ulla Lorentzen; Wali Hafezi; Wolfgang Schlumberger; Katja Steinhagen; Joachim Ewald Kühn
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

5.  Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses.

Authors:  C M Posavad; D M Koelle; M F Shaughnessy; L Corey
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

6.  Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1.

Authors:  Bruno Sainz; William P Halford
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes.

Authors:  Sara Tengvall; Annika Lundqvist; Roselyn J Eisenberg; Gary H Cohen; Ali M Harandi
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

8.  Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.

Authors:  Kiyomitsu Katsumata; Adriana Weinberg; Koji Chono; Shoji Takakura; Toru Kontani; Hiroshi Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

9.  Comparative performance of a novel herpes simplex virus type 2-specific enzyme-linked immunosorbent assay using a targeted chain oligopeptide, peptide 55.

Authors:  A M Al-Sulaiman; P J Vallely; P E Klapper
Journal:  Clin Vaccine Immunol       Date:  2009-04-15

10.  A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection.

Authors:  Ali M Harandi; Kristina Eriksson; Jan Holmgren
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.